What will the average number of measles cases be during Trump's term?
Assuming the market threshold is an average above 2,000 measles cases per year across 2025–2028, I assess a **57%** probability that the Trump Administration’s four-year average will exceed 2,000 cases — slightly more likely than not given two consecutive years already above 2,000 and the persistence signals from public-health reporting.
Analysis
**Stage 1 — Blind analysis (ignore market prices)**
The two strongest factual anchors are that (a) 2025 exceeded 2,000 U.S. measles cases and (b) 2026 has already passed 2,000 cases by mid‑June. Those observations materially shift the arithmetic for a four‑year average: to get a final average <=2,000 the sum of the four years must be <=8,000 cases. With 2025 and an in‑progress 2026 already together likely contributing ~4,000–5,000 cases under reasonable scenarios, 2027 and 2028 would need to be substantially below historical outbreak levels (well under ~1,500 each) to pull the mean below 2,000.
Arguments that push my independent probability upward: sustained under‑vaccinated pockets, persistent public‑health capacity constraints and policy signals described in reporting, and the epidemiologic reality that once measles establishes chains in undervaccinated communities outbreaks can recur across years. Those factors make a multi‑year elevation plausible and materially increase the chance the four‑year average stays above 2,000.
Arguments that pull the probability downward: measles is highly vaccine‑preventable, and concentrated, high‑coverage responses (catch‑up campaigns, school mandate reinforcements, federally supported outbreak control funding) can sharply reduce transmission even after bad years. Also, some late‑season dynamics and stochastic fade‑outs mean a mid‑year >2,000 reading for 2026 could still resolve into a moderate total if transmission wanes.
Balancing these, I judge persistence more likely than a quick reversion to pre‑2025 lows. I therefore place the independent probability that the 2025–2028 average exceeds 2,000 at **57%**.
**Stage 2 — Market calibration (compare to market price Yes: 0.31 / No: 0.69)**
The market is currently pricing the 'Yes' outcome at ~31%, substantially below my 57% independent estimate. Possible explanations for that gap:
- **Anchoring to long historical norms.** Many participants may still be anchored to pre‑2025 low baselines (tens to low hundreds), underweighting the significance of two consecutive >2,000 years and the non‑linear arithmetic of averaging across four years. - **Overconfidence in policy rebound.** Traders may overweight the likelihood and speed of corrective policy — e.g., rapid large catch‑up vaccination campaigns or federal support — which would materially lower subsequent year totals. - **Ambiguity or misunderstanding about the threshold.** If some traders are uncertain whether the threshold is exactly 2,000, or whether the outcome uses confirmed vs. provisional totals, they may price conservatively against 'Yes'. - **Risk aversion and liquidity effects.** The market may contain risk‑averse sellers pushing down 'Yes' price, or large early bets on 'No' creating momentum.
Given those factors, the market looks plausibly underpricing persistence risk. However, the market could also be correctly tagging genuine upside scenarios for mitigation: a strong vaccine push, improved surveillance and outbreak control, or that the mid‑2026 >2,000 reading does not scale to a high year‑end total. These are non‑trivial and justify some discount to my point estimate; I do not believe they justify the full ~26 percentage point gap. My recommended interpretation is that the market reflects significant uncertainty and optimism about corrective responses; my independent view is meaningfully higher.
Arguments
For
- Two consecutive calendar years (2025 and 2026) have already exceeded 2,000 cases — this materially raises the baseline for a four‑year average and makes reversion to a sub‑2,000 mean harder without sustained low subsequent years.
- Public reporting and expert statements describe outbreaks as unusually persistent and attribute some drivers to reduced public‑health support and policy shifts, implying higher structural risk of elevated case counts continuing.
- Measles spreads explosively in undervaccinated localities; the U.S. contains enough such pockets that recurring multi‑year outbreaks are epidemiologically plausible and have historically produced sustained elevated totals when conditions align.
Against
- Measles is vaccine‑preventable; targeted catch‑up campaigns, policy reversals on exemptions, or funded outbreak responses could sharply reduce future annual totals and pull the four‑year average below 2,000.
- Mid‑year provisional counts can overstate final year totals if late‑season transmission decreases or if case definitions/reporting adjustments change final numbers.
- The possibility of stochastic extinction of chains: even with early momentum, outbreaks can peter out quickly, making high early counts not necessarily predictive of sustained yearly totals.
Key drivers
- Vaccination coverage trends and local clustering of undervaccinated communities
- Federal and state public‑health funding, outbreak response scale, and policy changes affecting school/exemption rules
- Importation pressure and international measles activity (travel‑linked seeding)
- Natural outbreak dynamics (stochastic fadeout vs. sustained transmission chains)
Risk factors
- Rapid, well‑resourced catch‑up vaccination campaigns or emergency funding that sharply reduce transmission in 2027–2028
- Improved reporting changes (e.g., reclassification or data lag corrections) that reduce apparent year totals or change denominators
- Stochastic epidemic fadeout: despite early momentum, transmission can collapse for ecological or behavioral reasons
- Unexpected large international decline in measles circulation, reducing importations and secondary outbreaks
Scenarios
Best case
Sustained elevated transmission: 2025 and 2026 remain high (each ~2,000–3,500), and 2027–2028 also experience notable outbreaks (each ~1,800–2,500), producing a four‑year average comfortably above 2,000. This would be driven by persistent undervaccination, limited policy correction, and repeated importations.
Most likely
Partial correction with lingering transmission: 2025 and 2026 remain above 2,000 (final 2026 somewhat uncertain), and 2027–2028 decline but not to pre‑2025 lows (each ~1,200–1,800), producing a four‑year average near the threshold and slightly favoring >2,000.
Worst case
Rapid successful mitigation: aggressive catch‑up vaccination and strengthened school‑entry requirements in 2026–2027 plus enhanced federal outbreak support lead to large drops in 2027–2028 (annual totals fall to a few hundred), resulting in a four‑year average well below 2,000.
More from this day
- FinancialsKalshi1y
What sector will SpaceX be assigned to in the S&P?
AI6%MKT93%Edge-87HypedI assess a low probability (~6%) that SpaceX will be assigned to Communication Services; the preponderance of evidence (Morningstar/CRSP and GICS-style classification logic) points to an Industrials assignment.
- politicsPolymarketEnded
Where will the next US-Iran diplomatic meeting happen?
AI40%MKT5%Edge+35Hidden GemGiven the short two-week window and the history of periodic mediated contacts, a meeting is more likely than not, but nontrivial logistical, political, and incentive barriers make a failure to meet within this window plausible; I assess a 40% chance that no qualifying in-person US–Iran diplomatic meeting will occur by June 30, 2026.
- SportsKalshi1y
Will Scottie Scheffler win the grand slam before 2028?
AI35%MKT4%Edge+31Hidden GemScottie Scheffler has a meaningful path to complete the career Grand Slam before 2028, but it is far from a longshot — my independent assessment is that he has a ~35% chance, considerably higher than the current market price of 6%.